Education Meeting - 2018 ILTS Consensus Conference

NAFLD/NASH: From medical treatment to liver transplantation

Meeting content A—Z

Date Added A—Z

Are we eliminating HCV also in special population?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Felice Nava
- 2018 ILTS Consensus Conference
End-stage liver disease and liver transplantation

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Marina Berenguer
- 2018 ILTS Consensus Conference
Epidemiology and prevention

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Zobair M. Younoussi
- 2018 ILTS Consensus Conference
ILTS NAFLD/NASH Consensus Conference 2018: Summary of Recommendations

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Cardiac Disease
- 2018 ILTS Consensus Conference
Management of recurrent and de novo NAFLD/NASH after liver transplantation

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Kymberly Watt
- 2018 ILTS Consensus Conference
Medical treatment: life style changes and pharmachological therapy

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Vlad Ratziu
- 2018 ILTS Consensus Conference
Pediatric population

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Anil Dhawan
- 2018 ILTS Consensus Conference
Risk of hepatocellular carcinoma: surveillance and management

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Christian Toso
- 2018 ILTS Consensus Conference
Why NASH? Because HCV disappears?

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- Alfredo Alberti
- 2018 ILTS Consensus Conference
Working group presentation: End-stage liver disease and liver transplantation

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- 2018 ILTS Consensus Conference
Working group presentation: Epidemiology and prevention

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- 2018 ILTS Consensus Conference
Working group presentation: Management of recurrent and de novo NAFLD/NASH after liver transplantation

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- 2018 ILTS Consensus Conference
Working group presentation: Medical treatment: lifestyle changes and pharmacological therapy

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- 2018 ILTS Consensus Conference
Working group presentation: Risk of hepatocellular carcinoma: surveillance and management

For ILTS members only, please join now or renew your membership.

For ILTS members only, please join now or renew your membership.
- Hepatology
- 2018 ILTS Consensus Conference

International Liver Transplantation Society

Education Meeting - 2018 ILTS Consensus Conference

NAFLD/NASH: From medical treatment to liver transplantation

Are we eliminating HCV also in special population?

End-stage liver disease and liver transplantation

Epidemiology and prevention

ILTS NAFLD/NASH Consensus Conference 2018: Summary of Recommendations

Management of recurrent and de novo NAFLD/NASH after liver transplantation

Medical treatment: life style changes and pharmachological therapy

Pediatric population

Risk of hepatocellular carcinoma: surveillance and management

Why NASH? Because HCV disappears?

Working group presentation: End-stage liver disease and liver transplantation

Working group presentation: Epidemiology and prevention

Working group presentation: Management of recurrent and de novo NAFLD/NASH after liver transplantation

Working group presentation: Medical treatment: lifestyle changes and pharmacological therapy

Working group presentation: Risk of hepatocellular carcinoma: surveillance and management

Specialty Sections

Content Directories